• OTS
  • April 30, 2018
SHARE
Post Views: 804

Naqvi I, Gunaratne R, McDade JE, Moreno A, Rempel RE, Rouse DC, Herrera SG, Pisetsky DS, Lee J, White RR, Sullenger BA.
Mol Ther. 2018 Apr 4;26(4):1020-1031.

PubMed

Related articles

Hybridization Liquid Chromatography-Tandem Mass Spectrometry: An Alternative Bioanalytical Method for Antisense Oligonucleotide Quantitation in Plasma and Tissue Samples.

Hybridization Liquid Chromatography-Tandem Mass Spectrometry: An Alternative Bioanalytical Method for Antisense Oligonucleotide Quantitation in Plasma and Tissue Samples.

August 5th, 2020
Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists

Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists

July 5th, 2020
Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics.

Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics.

July 5th, 2020
Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial

Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial

May 15th, 2020
Vaccination against non-mutated neoantigens induced in recurrent and future tumors

Vaccination against non-mutated neoantigens induced in recurrent and future tumors

April 30th, 2020
Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses

Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses

February 29th, 2020